Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06846554 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06846554 · ClinicalTrials.gov record · last posted 2026-05-11

A Trial of "APL-9796'' in Adults With Pulmonary Hypertension

Study acronym: ViTAL-PH
StatusRecruiting
PhasePhase 2
Started2025-04-09
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The AP13CP02 study is a phase 2, open-label, dose escalation trial to determine how safe and tolerable multiple subcutaneous (SC) injections of APL-9796 are for patients with PH. The study will also assess how effective APL-9796 could be for treating patients with PH and whether the body produces antibodies working against APL-9796. The trial will be conducted in two parts: * Part A: Up to 36 adults with WHO Group 1 Pulmonary arterial hypertension (PAH). * Part B (optional): Up to 12 adults with WHO Group 3 - PH associated with ILD (PH-ILD).

Amendment record 4 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 4 times since 2025-02-20; most recent amendment 2026-05-06. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-04-10
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT06846554
Lead Sponsor Apollo Therapeutics Ltd
Conditions Pulmonary Arterial Hypertension
Enrollment 48 participants
Start Date 2025-04-09
Primary Completion 2027-08-30 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-11